VACCINEX, INC. (VCNX)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 600K 1.2M 1.8M Q4 '18: 724K Q1 '19: 612K Q2 '19: 511K Q3 '19: 717K Q4 '19: 523K Q2 '21: 1.5M Q3 '21: 900K Q4 '21: 900K Q2 '23: 825K Q3 '23: 795K Q4 '23: 570K Q1 '24: 124K Q2 '24: 356K Q3 '24: 388K Q4 '24: 601K Q4 '18 Q2 '19 Q4 '19 Q3 '21 Q2 '23 Q4 '23 Q2 '24 Q4 '24

Gross Profit TTM

-450K -300K -150K 0 150K 300K 450K Q4 '18: -309K Q1 '19: -356K Q2 '19: -227K Q3 '19: 217K Q4 '19: 324K Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-45M -30M -15M 0 15M 30M 45M Q4 '17: -21.1M Q1 '18: -21.9M Q2 '18: -23.8M Q3 '18: -24.9M Q4 '18: -27.3M Q1 '19: -30.7M Q2 '19: -33M Q3 '19: -34.2M Q4 '19: -32M Q1 '20: -30M Q2 '20: -27.7M Q3 '20: -28.6M Q4 '20: -28.3M Q1 '21: -27.4M Q2 '21: -26.6M Q3 '21: -23.1M Q4 '21: -22.5M Q1 '22: -20.8M Q2 '22: -20.6M Q3 '22: -20.3M Q4 '22: -19.9M Q1 '23: -20.3M Q2 '23: -22M Q3 '23: -23M Q4 '23: -22.9M Q1 '24: -23M Q2 '24: -21.6M Q3 '24: -20.3M Q4 '24: -18.7M Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Net Income TTM

-45M -30M -15M 0 15M 30M 45M Q4 '17: -18.7M Q1 '18: -20.9M Q2 '18: -22.6M Q3 '18: -23.7M Q4 '18: -29.5M Q1 '19: -30.7M Q2 '19: -32.9M Q3 '19: -34M Q4 '19: -31.9M Q1 '20: -29.9M Q2 '20: -27.6M Q3 '20: -28.7M Q4 '20: -28.8M Q1 '21: -28.3M Q2 '21: -27.7M Q3 '21: -24.2M Q4 '21: -22.4M Q1 '22: -20.4M Q2 '22: -19.8M Q3 '22: -19.4M Q4 '22: -19.8M Q1 '23: -20.2M Q2 '23: -21.9M Q3 '23: -22M Q4 '23: -20.3M Q1 '24: -19.2M Q2 '24: -17.8M Q3 '24: -18.6M Q4 '24: -18.6M Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Cost of Revenue TTM

0 400K 800K 1.2M Q4 '18: 1M Q1 '19: 968K Q2 '19: 738K Q3 '19: 500K Q4 '19: 199K Q4 '18 Q1 '19 Q2 '19 Q3 '19 Q4 '19

Operating Cash Flow TTM

-45M -30M -15M 0 15M 30M 45M Q2 '18: -21.5M Q3 '18: -24M Q4 '18: -25.3M Q1 '19: -28.6M Q2 '19: -29.2M Q3 '19: -32.5M Q4 '19: -30.7M Q1 '20: -29.7M Q2 '20: -29.3M Q3 '20: -28.1M Q4 '20: -28.6M Q1 '21: -28.3M Q2 '21: -29.8M Q3 '21: -26.5M Q4 '21: -25.3M Q1 '22: -23.2M Q2 '22: -21.5M Q3 '22: -19.6M Q4 '22: -19.1M Q1 '23: -19.1M Q2 '23: -19.3M Q3 '23: -18.2M Q4 '23: -21.4M Q1 '24: -21M Q2 '24: -19.9M Q3 '24: -20M Q4 '24: -16.2M Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

Free Cash Flow TTM

-30M -15M 0 15M 30M 45M Q2 '18: -21.6M Q3 '18: -24M Q4 '18: -25.5M Q2 '20: -29.5M Q3 '20: -28.4M Q4 '20: -28.9M Q2 '23: -19.4M Q3 '23: -18.3M Q4 '23: -21.4M Q1 '24: -21M Q2 '24: -19.9M Q3 '24: -20M Q4 '24: -16.2M Q2 '18 Q4 '18 Q3 '20 Q2 '23 Q4 '23 Q2 '24 Q4 '24

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q2 '21: 28.6M Q3 '21: 30.8M Q1 '22: 38.8M Q2 '22: 42.7M Q3 '22: 2.8M Q1 '23: 237.5K Q2 '23: 287.7K Q3 '23: 322.2K Q1 '24: 1.3M Q2 '24: 1.8M Q3 '24: 2M Q2 '21 Q1 '22 Q3 '22 Q2 '23 Q1 '24 Q3 '24

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-180.00 -120.00 -60.00 0.00 60.00 120.00 180.00 Q4 '17: -19.90 Q1 '18: -21.11 Q2 '18: -22.68 Q3 '18: -17.86 Q4 '18: -5.65 Q1 '19: 0.69 Q2 '19: 6.64 Q3 '19: 7.01 Q4 '19: -2.50 Q1 '20: -2.16 Q2 '20: -1.78 Q3 '20: -1.66 Q4 '20: -1.55 Q1 '21: -1.36 Q2 '21: -1.18 Q3 '21: -0.91 Q4 '21: -0.79 Q1 '22: -0.65 Q2 '22: -0.57 Q3 '22: -2.07 Q4 '22: -94.63 Q1 '23: -115.40 Q2 '23: -139.81 Q3 '23: -153.39 Q4 '23: -43.68 Q1 '24: -25.73 Q2 '24: -4.29 Q3 '24: 8.13 Q4 '24: -8.90 Q4 '17 Q4 '18 Q4 '19 Q4 '20 Q4 '21 Q4 '22 Q4 '23 Q4 '24

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.